United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 6

Name: Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 6 comparison snapshot
Creator: Fliar BI Prism

A five-company biological products, excluding disgnostic substances cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderAdagio · 46

Strongest available pathChampion Oncology · -48.2%

Widest latest marginChampion Oncology · 8.3%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1IVVD · Nasdaq

Adagio

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2022Waltham, Massachusetts$284.3M market cap

View full Companies Radar profile

46Cautious

Snapshot price$0.96as of page date

Monthly-close return-97.3%five-year window

FY2025 revenue$0.05BInvivyd, Inc.

Net margin-98.2%FY2025

P/E snapshot-1.8xone ratio, not a verdict

Prism attention24.5%share across these five

Filing track recordRevenue, USD billions

+110.5%

FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 110.5%

52-week position17% through range

$0.53$3.07

News mentions2.2K

Community mentions0partial coverage

U.S.-scope patents187

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal54/100
Management stability90/100
Market position3/100
Capital-event signal60/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 7 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2VIR · Nasdaq

Vir Biotechnology

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2017San Francisco$1.83B market cap

View full Companies Radar profile

46Cautious

Snapshot price$10.83as of page date

Monthly-close return-78.1%five-year window

FY2025 revenue$0.07BVir Biotechnology, Inc.

Net margin-638.9%FY2025

P/E snapshot-4.3xone ratio, not a verdict

Prism attention29.0%share across these five

Filing track recordRevenue, USD billions

-7.6%

FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -7.6%

52-week position88% through range

$4.75$11.66

News mentions2.6K

Community mentions52partial coverage

U.S.-scope patents423

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal31/100
Management stability90/100
Market position26/100
Capital-event signal66/100
Innovation pulse20/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 10 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3RXRX · Nasdaq

Recursion

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2013New York$1.79B market cap

View full Companies Radar profile

45Cautious

Snapshot price$3.34as of page date

Monthly-close return-86.4%five-year window

FY2025 revenue$0.07BRECURSION PHARMACEUTICALS, INC.

Net margin-863.4%FY2025

P/E snapshot-3.7xone ratio, not a verdict

Prism attention25.5%share across these five

Filing track recordRevenue, USD billions

+633.7%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 64.6%

52-week position13% through range

$2.77$7.18

News mentions2.3K

Community mentions0partial coverage

U.S.-scope patents247

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal44/100
Management stability90/100
Market position13/100
Capital-event signal75/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 6 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 7 M&A involvements, 1 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4EDIT · Nasdaq

Editas Medicine

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2013Cambridge, Massachusetts$485.3M market cap

View full Companies Radar profile

43Cautious

Snapshot price$3.16as of page date

Monthly-close return-94.8%five-year window

FY2025 revenue$0.04BEditas Medicine, Inc.

Net margin-395.0%FY2025

P/E snapshot-4.2xone ratio, not a verdict

Prism attention18.8%share across these five

Filing track recordRevenue, USD billions

+58.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.2%

52-week position52% through range

$1.66$4.54

News mentions1.7K

Community mentions142partial coverage

U.S.-scope patents714

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal50/100
Management stability90/100
Market position0/100
Capital-event signal65/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5CSBR · Nasdaq

Champion Oncology

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1985Hackensack, New Jersey$68.5M market cap

View full Companies Radar profile

36Cautious

Snapshot price$4.93as of page date

Monthly-close return-48.2%five-year window

FY2025 revenue$0.06BCHAMPIONS ONCOLOGY, INC.

Net margin8.3%FY2025

Prism attention2.2%share across these five

Filing track recordRevenue, USD billions

+38.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 8.5%

52-week position3% through range

$4.83$8.74

News mentions194

Community mentions0partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal47/100
Management stability90/100
Market position0/100
Capital-event signal30/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Champion Oncology

-48.2%

Vir Biotechnology

-78.1%

Recursion

-86.4%

Editas Medicine

-94.8%

Adagio

-97.3%

Latest revenue

USD billions, official filing scope shown on each company card.

Recursion

$0.07B

Vir Biotechnology

$0.07B

Champion Oncology

$0.06B

Adagio

$0.05B

Editas Medicine

$0.04B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Champion Oncology

8.3%

Adagio

-98.2%

Editas Medicine

-395.0%

Vir Biotechnology

-638.9%

Recursion

-863.4%

Prism news attention

Normalized share across these five names; attention is not quality.

Vir Biotechnology

29.0%

Recursion

25.5%

Adagio

24.5%

Editas Medicine

18.8%

Champion Oncology

2.2%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Vir Biotechnology leads the conversation

It holds 29.0% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $0.07B.

Price path

Champion Oncology leads the available price paths

Its monthly-close return is -48.2% for the five-year window. At the other end, Adagio is -97.3% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Champion Oncology has the widest latest margin

Its FY2025 net margin is 8.3%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Vir Biotechnology shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -4.3x while its five-year window price return is -78.1%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · IVVD

Adagio

2,170available Prism news records

Prism top themes

Leadership & governance

Price action & investor response

Legal, arbitration & regulatory

Earnings & financial performance

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+19.9%470 latest 12m vs 392 prior 12m

Machine-classified coverage tone

90.8% positive+3.0 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

classical symphony 132classical period symphony 13218th century symphony 131classical orchestral 123orchestral conducting 46orchestral suite 45viennese symphony 43viral vector vaccines 30

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-07-15 · trend and themes shown through 2026-07

Areas of research · VIR

Vir Biotechnology

2,561available Prism news records

Prism top themes

Price action & investor response

Capital allocation & transactions

Legal, arbitration & regulatory

Leadership & governance

Earnings & financial performance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+31.8%319 latest 12m vs 242 prior 12m

Machine-classified coverage tone

91.1% positive-0.6 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

company valuation 24stock price 20startup valuation 19cancer biomarkers 18stock performance 17tumor microenvironment 12investigational new vaccine 11vaccine candidate selection 10

Keyword tag occurrences in available Prism news records.

Coverage: 2013-08-08–2026-06-19 · trend and themes shown through 2026-06

Areas of research · RXRX

Recursion

2,254available Prism news records

Prism top themes

Price action & investor response

Leadership & governance

Capital allocation & transactions

Legal, arbitration & regulatory

Earnings & financial performance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-26.9%351 latest 12m vs 480 prior 12m

Machine-classified coverage tone

90.9% positive-1.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

drug repurposing ai 156machine learning drug discovery 107neural networks drug design 91ai toxicity prediction 51drug design 51deep learning biology 47pharmacogenomics 37ai screening 26

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-01–2026-06-13 · trend and themes shown through 2026-06

Areas of research · EDIT

Editas Medicine

1,665available Prism news records

Prism top themes

Price action & investor response

Legal, arbitration & regulatory

Leadership & governance

Capital allocation & transactions

Earnings & financial performance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-15.9%164 latest 12m vs 195 prior 12m

Machine-classified coverage tone

90.2% positive-2.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

crispr-cas9 68crispr applications 68gene therapy rare diseases 68cell-based therapies 27stem cell banking 27gene knockout 24gene delivery systems 20gene therapy studies 18

Keyword tag occurrences in available Prism news records.

Coverage: 2013-11-25–2026-06-03 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

VIR

Vir Biotechnology

52 mentions

Stock and valuation

Products, pricing and logistics

Other company context

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 52 records remained after filtering.

EDIT

Editas Medicine

142 mentions

Stock and valuation

Products, pricing and logistics

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 142 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

IVVD

Adagio

through 2026-02-26

Company announcements 7Lawsuits 3Listing / IPO 2Leadership changes 1

2026-02-26
Company announcements
This commitment was demonstrated in 2025 by the launch of a Green Key certification process
2025-02-14
Listing / IPO
Adagio Therapeutics Inc., of Waltham, Mass., launched its upsized IPO at the $17 per share midpoint to raise $309 million.
2025-01-10
Leadership changes
Adagio, the European leader in aparthotels, announces the appointment of Sophie Mestiri as Chief Human Resources Officer and member of the Executive Committee.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

VIR

Vir Biotechnology

through 2026-02-27

Leadership changes 7Earnings releases 6Business contracts 4Listing / IPO 2Company announcements 1

2026-02-27
Business contracts
Astellas Pharma Inc. and Vir Biotechnology Inc. have signed a global co-development pact to advance VIR-5500, Vir’s PRO-XTEN dual-masked CD3 T-cell engager targeting prostate-specific membrane antigen for treating prostate cancer. Under the deal terms, San Francisco-based Vir will receive $335 million in up-front and near-term payments, including $240 million in cash, $75 million in equity investment and a $20 million near-term milestone. Vir is also eligible to receive up to $1.37 billion in development, regulatory and sales-based milestones plus royalties on ex-U.S. sales.
2026-02-24
Listing / IPO
Vir Biotechnology, Inc. (Nasdaq: VIR ), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer $200,000,000 of shares of its common stock in an underwritten public offering.
2026-02-24
Company announcements
Vir Biotechnology Inc (NASDAQ: VIR) entered a partnership with Astellas to develop a prostate cancer therapy, securing significant upfront and milestone payments.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RXRX

Recursion

through 2026-02-27

Earnings releases 24Leadership changes 13Company announcements 9M&A 7Listing / IPO 2

2026-02-27
M&A
In recent days, his firm acquired a significant amount of shares from Recursion Pharmaceuticals, a biotechnology company that uses artificial intelligence to accelerate
2026-02-25
Earnings releases
We ended the year with $754 million in cash.
2025-11-21
Leadership changes
Current CEO Chris Gibson, one of the founders of the company, announced earlier this month that he would step down, telling STAT that Recursion, which is moving toward later-stage development programs, needed a leader with a different skill set. Gibson is becoming board chair.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

EDIT

Editas Medicine

through 2026-01-01

Earnings releases 9Leadership changes 8Listing / IPO 2

2026-01-01
Leadership changes
Editas Medicine, Inc., a genome editing company, has appointed Bernadette Connaughton to its board of directors.
2025-04-01
Earnings releases
Zacks Research also issued estimates for Editas Medicine’s Q3 2025 earnings at ($0.65) EPS.
2025-02-14
Listing / IPO
Editas Medicine Inc. filed an S-1 with the SEC seeking to raise up to $100 million, including overallotments, in an IPO.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CSBR

Champion Oncology

through 2025-03-12

Earnings releases 16Leadership changes 2

2025-03-12
Earnings releases
Year to Date Highlights: Total revenue increased 23% to $44.6 million
2025-01-09
Leadership changes
Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.
2025-03-11
Earnings releases
Total revenue increased 42% to $17.0 million

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence

2020 extracted base$194.20B–$477.15B

2033 extracted forecast$685.30B–$1.37T

Implied source CAGR8.5%

high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records

Latest 12m volume+9.8%10786 vs 9825 records

Positive classified tone41.7%+4.6 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies

4,078

substance abuse education

3,736

opioid addiction and treatment

3,643

overdose prevention techniques

3,482

controlled substance regulations

3,381

substance abuse overdose fatalities

3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576cannabis policy reform discussions 1,328psychedelic mental health studies 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 26–33. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Adagio leads the readiness ranking

Its Prism readiness score is 46/100, the highest in this five-company comparison.

Open Adagio in Companies Radar

Scale and margin leadership sit with Recursion and Champion Oncology

Recursion has the largest displayed latest revenue at $0.07B; Champion Oncology has the widest displayed latest margin at 8.3%.

Open Recursion in Companies Radar Open Champion Oncology in Companies Radar

Comparisons

Strongest versus weakest available price path

Champion Oncology is -48.2% for its five-year window; Adagio is -97.3% for its five-year window.

Open Champion Oncology in Companies Radar Open Adagio in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.07B for Recursion to $0.04B for Editas Medicine. Entity and filing-period labels remain visible on the company cards.

Open Recursion in Companies Radar Open Editas Medicine in Companies Radar

Anomalies

Adagio has the widest attention-readiness rank gap

It ranks #3 by measured news attention (24.5%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Adagio in Companies Radar

Recursion shows a price-operating divergence to inspect

Its displayed filing-revenue change is +633.7% while its available monthly-close return is -86.4%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Recursion in Companies Radar

Explanations

Attention measures coverage volume, not quality

Vir Biotechnology's 29.0% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Vir Biotechnology in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Adagio's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 46/100 score.

Open Adagio in Companies Radar

Stress-test the largest divergence before forming a view

Compare Recursion's profile with Champion Oncology's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Recursion in Companies Radar Open Champion Oncology in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.